Anti-C5a Vilobelimab Reduces All-cause Mortality in Critically Ill COVID-19 Patients and in Those With Severe ARDS: A Phase 3 Randomized Double-blind, Placebo-controlled Study
M. Witzenrath,A. P. J. Vlaar,M. Bauer,D. Annane,L. Heunks,B. Mourvillier,L. Hercilla Vasquez,T. Welte,P. van Paassen,S. de Bruin,E. H. T. Lim,M. C. Brouwer,P. R. Tuinman,J. F. Saraiva,G. Marx,S. M. Lobo,R. Boldo,J. Simon-Campos,A. D. Cornet,A. Grebenyuk,J. Engelbrecht,M. Habel,C. Thielert,J. Dickinson,S. Rueckinger,R. Zerbib,D. Neukirchen,K. Pilz,R. Guo,D. van de Beek,N. C. Riedemann
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE（2023）
